DOCSLIB.ORG

Guidelines of Hypertension – 2020 Barroso Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Guidelines of Hypertension – 2020 Barroso Et Al Brazilian Guidelines of Hypertension – 2020 Barroso et al. Guidelines Brazilian Guidelines of Hypertension – 2020 Development: Department of Hypertension of the Brazilian Society of Cardiology (DHA-SBC), Brazilian Society of Hypertension (SBH), Brazilian Society of Nephrology (SBN) Norms and Guidelines Council (2020-2021): Brivaldo Markman Filho, Antonio Carlos Sobral Sousa, Aurora Felice Castro Issa, Bruno Ramos Nascimento, Harry Correa Filho, Marcelo Luiz Campos Vieira Norms and Guidelines Coordinator (2020-2021): Brivaldo Markman Filho General Coordinator: Weimar Kunz Sebba Barroso Coordination Work Group: Weimar Kunz Sebba Barroso, Cibele Saad Rodrigues, Luiz Aparecido Bortolotto, Marco Antônio Mota-Gomes Guideline Authors: Weimar Kunz Sebba Barroso,1,2 Cibele Isaac Saad Rodrigues,3 Luiz Aparecido Bortolotto,4 Marco Antônio Mota-Gomes,5 Andréa Araujo Brandão,6 Audes Diógenes de Magalhães Feitosa,7,8 Carlos Alberto Machado,9 Carlos Eduardo Poli-de-Figueiredo,10 Celso Amodeo,11 Décio Mion Júnior,12 Eduardo Costa Duarte Barbosa,13 Fernando Nobre,14,15 Isabel Cristina Britto Guimarães,16 José Fernando Vilela- Martin,17 Juan Carlos Yugar-Toledo,17 Maria Eliane Campos Magalhães,18 Mário Fritsch Toros Neves,6 Paulo César Brandão Veiga Jardim,2,19 Roberto Dischinger Miranda,11 Rui Manuel dos Santos Póvoa,11 Sandra C. Fuchs,20 Alexandre Alessi,21 Alexandre Jorge Gomes de Lucena,22 Alvaro Avezum,23 Ana Luiza Lima Sousa,1,2 Andrea Pio-Abreu,24 Andrei Carvalho Sposito,25 Angela Maria Geraldo Pierin,24 Annelise Machado Gomes de Paiva,5 Antonio Carlos de Souza Spinelli,26 Armando da Rocha Nogueira,27 Nelson Dinamarco,28 Bruna Eibel,29,30 Cláudia Lúcia de Moraes Forjaz,31 Claudia Regina de Oliveira Zanini,1,2 Cristiane Bueno de Souza,9 Dilma do Socorro Moraes de Souza,31 Eduardo Augusto Fernandes Nilson,24,32 Elisa Franco de Assis Costa,1 Elizabete Viana de Freitas,6,33 Elizabeth da Rosa Duarte,34 Elizabeth Silaid Muxfeldt,26,35 Emilton Lima Júnior,36 Erika Maria Gonçalves Campana,6,37 Evandro José Cesarino,38,39 Fabiana Marques,40 Fábio Argenta,41 Fernanda Marciano Consolim-Colombo,42 Fernanda Spadotto Baptista,12 Fernando Antonio de Almeida,3 Flávio Antonio de Oliveira Borelli,43 Flávio Danni Fuchs,44 Frida Liane Plavnik,4,23 Gil Fernando Salles,27 Gilson Soares Feitosa,45 Giovanio Vieira da Silva,12 Grazia Maria Guerra,4,46 Heitor Moreno Júnior,25 Helius Carlos Finimundi,47 Isabela de Carlos Back,48 João Bosco de Oliveira Filho,49 João Roberto Gemelli,50 José Geraldo Mill,51 José Marcio Ribeiro,52,53 Leda A. Daud Lotaif,43,54 Lilian Soares da Costa,55 Lucélia Batista Neves Cunha Magalhães,56 Luciano Ferreira Drager,4 Luis Cuadrado Martin,57 Luiz César Nazário Scala,58 Madson Q. Almeida,12 Marcia Maria Godoy Gowdak,59 Marcia Regina Simas Torres Klein,24 Marcus Vinícius Bolívar Malachias,52 Maria Cristina Caetano Kuschnir,6 Maria Eliete Pinheiro,60 Mario Henrique Elesbão de Borba,61 Osni Moreira Filho,62 Oswaldo Passarelli Júnior,43 Otavio Rizzi Coelho,25 Priscila Valverde de Oliveira Vitorino,63 Renault Mattos Ribeiro Junior,64 Roberto Esporcatte,6,65 Roberto Franco,57 Rodrigo Pedrosa,8 Rogerio Andrade Mulinari,21 Rogério Baumgratz de Paula,66 Rogério Toshiro Passos Okawa,67,68 Ronaldo Fernandes Rosa,69 Sandra Lia do Amaral,57 Sebastião R. Ferreira-Filho,70 Sergio Emanuel Kaiser,6 Thiago de Souza Veiga Jardim,1 Vanildo Guimarães,71 Vera H. Koch,24 Wille Oigman,6 Wilson Nadruz25 Universidade Federal de Goiás,1 Goiânia, GO – Brazil Liga de Hipertensão Arterial, 2 Goiânia, GO – Brazil Pontifícia Universidade Católica de São Paulo, Faculdade de Ciências Médicas e da Saúde,3 Sorocaba, SP – Brazil Instituto do Coração (InCor),4 São Paulo, SP – Brazil Centro Universitário CESMAC,5 Maceió, AL – Brazil Faculdade de Ciências Médicas da Universidade do Estado do Rio de Janeiro (FCM-UERJ),6 Rio de Janeiro, RJ – Brazil Universidade Federal de Pernambuco,7 Recife, PE – Brazil Pronto Socorro Cardiológico de Pernambuco (PROCAPE),8 Recife, PE – Brazil Secretaria Municipal de Saúde de Campos do Jordão,9 Campos do Jordão, SP – Brazil Pontifícia Universidade Católica do Rio Grande do Sul,10 Porto Alegre, RS – Brazil Universidade Federal de São Paulo (UNIFESP),11 São Paulo, SP – Brazil Hospital das Clínicas da Faculdade de Medicina da USP,12 São Paulo, SP – Brazil Serviço Hipertensão e Cardiometabolismo da Santa Casa de Porto Alegre,13 Porto Alegre, RS – Brazil Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo,14 Ribeirão Preto, SP – Brazil Hospital São Francisco,15 Ribeirão Preto, SP – Brazil Universidade Federal da Bahia (UFBA),16 Salvador, BA – Brazil Faculdade Estadual de Medicina de São José do Rio Preto,17 São José do Rio Preto, SP – Brazil Hospital Universitário Pedro Ernesto da Universidade do Estado do Rio de Janeiro (UERJ),18 Rio de Janeiro, RJ – Brazil Hospital do Coração de Goiás,19 Goiânia, GO – Brazil Faculdade de Medicina da Universidade Federal do Rio Grande do Sul (UFRGS),20 Porto Alegre, RS – Brazil DOI: https://doi.org/10.36660/abc.20201238 Arq Bras Cardiol. 2021; 116(3):516-658 516 Brazilian Guidelines of Hypertension – 2020 Barroso et al. Guidelines Universidade Federal do Paraná (UFPR),21 Curitiba, PR – Brazil Hospital Agamenom Magalhães,22 Recife, PE – Brazil Hospital Alemão Oswaldo Cruz,23 São Paulo, SP – Brazil Universidade de São Paulo (USP),24 São Paulo, SP – Brazil Universidade Estadual de Campinas (UNICAMP),25 Campinas, São Paulo – Brazil Cardiocentro,26 Natal, RN – Brazil Universidade Federal do Rio de Janeiro (UFRJ),27 Rio de Janeiro, RJ – Brazil Universidade Estadual de Santa Cruz,28 Ilhéus, BA – Brazil Instituto de Cardiologia, Fundação Universitária de Cardiologia (IC/FUC),29 Porto Alegre, RS – Brazil Centro Universitário da Serra Gaúcha (FSG),30 Caxias do Sul, RS – Brazil Universidade Federal do Pará (UFPA),31 Belém, PA – Brazil Ministério da Saúde,32 Brasília, DF – Brazil Departamento de Cardiogeriatria da Sociedade Brasileira de Cardiologia,33 Rio de Janeiro, RJ – Brazil Hospital Nossa Senhora da Conceição (HNSC),34 Tubarão, SC – Brazil Universidade Estácio de Sá (UNESA),35 Rio de Janeiro, RJ – Brazil Hospital de Clínicas da Universidade Federal do Paraná (HC/UFPR),36 Curitiba, PR – Brazil Universidade Iguaçu (UNIG),37 Rio de Janeiro, RJ – Brazil Faculdade de Ciências Farmacêuticas de Ribeirão Preto da Universidade de São Paulo,38 Ribeirão Preto, SP – Brazil Associação Ribeirãopretana de Ensino, Pesquisa e Assistência ao Hipertenso (AREPAH),39 Ribeirão Preto, SP – Brazil Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo,40 Ribeirão Preto, SP – Brazil Mediodonto,41 Cuiabá, MT – Brazil Programa de Pós-Graduação em Medicina da Universidade Nove de Julho (UNINOVE),42 São Paulo, SP – Brazil Instituto Dante Pazzanese de Cardiologia,43 São Paulo, SP – Brazil Hospital de Clínicas de Porto Alegre,44 Porto Alegre, RS – Brazil Escola Bahiana de Medicina e Saúde Pública,45 Salvador, BA – Brazil Universidade Santo Amaro (UNISA),46 São Paulo, SP – Brazil Universidade de Caxias do Sul (UCS),47 Caxias do Sul, RS – Brazil Universidade Federal de Santa Catarina (UFSC),48 Florianópolis, SC – Brazil Hospital Israelita Albert Einstein,49 São Paulo, SP – Brazil Clínica Gemelli,50 Porto Velho, RO – Brazil Centro de Ciências da Saúde, Universidade Federal do Espírito Santo,51 Vitória, ES – Brazil Faculdade Ciências Médicas de Minas Gerais,52 Belo Horizonte, MG – Brazil Hospital Felício Rocho,53 Belo Horizonte, MG – Brazil Hospital do Coração (HCor),54 São Paulo, SP – Brazil Instituto Estadual de Cardiologia Aloysio de Castro,55 Rio de Janeiro, RJ – Brazil Centro Universitário de Tecnologia e Ciência (UniFTC),56 Salvador, BA – Brazil Universidade Estadual Paulista (UNESP),57 Bauru, SP – Brazil Faculdade de Medicina da Universidade Federal de Mato Grosso,58 Cuiabá, MT – Brazil Instituto Vera Cruz,59 São Paulo, SP – Brazil Sociedade Brasileira de Nefrologia,60 São Paulo – Brazil Cardio Clínica do Vale,61 Lajeado, RS – Brazil Pontifícia Universidade Católica do Paraná,62 Curitiba, PR – Brazil Pontifícia Universidade Católica de Goiás,63 Goiânia, GO – Brazil Cardios Vita Centro de Medicina Cardiológica,64 Brasília, DF – Brazil Hospital Pró-Cradíaco,65 Rio de Janeiro, RJ – Brazil Universidade Federal de Juiz de Fora,66 Juiz de Fora, MG – Brazil Avancor Cardiologia,67 Maringá, PR – Brazil Universidade Estadual de Maringá,68 Maringá, PR – Brazil Faculdade de Ciências Médicas da Santa Casa de São Paulo,69 São Paulo – Brazil Universidade Federal de Uberlândia,70 Uberlândia, MG – Brazil Hospital Getúlio Vargas,71 Recife, PE – Brazil 1. DEFINITION, EPIDEMIOLOGY, AND PRIMARY PREVENTION Coordinator: Paulo César Brandão Veiga Jardim Deputy coordinator: Frida Liane Plavnik Members: Eduardo Augusto Fernandes Nilson, Evandro José Cesarino, Lucélia Batista Neves Cunha Magalhães 2. BLOOD PRESSURE AND VASCULAR DAMAGE Coordinator: Eduardo Costa Duarte Barbosa Deputy coordinator: Flávio Danni Fuchs Members: Bruna Eibel, José Geraldo Mill, Rogério Toshiro Passos Okawa 3. DIAGNOSIS AND CLASSIFICATION Coordinator: Marco Antônio Mota Gomes Deputy coordinator: Audes Diógenes de Magalhães Feitosa, Wilson Nadruz Members: Annelise Machado Gomes de Paiva, Fábio Argenta, João Bosco de Oliveira Filho 517 Arq Bras Cardiol. 2021; 116(3):516-658 Brazilian Guidelines of Hypertension – 2020 Barroso et al. Guidelines 4. CLINICAL AND COMPLEMENTARY ASSESSMENT Coordinator: Rui Manuel dos Santos Póvoa Deputy coordinators: Armando da Rocha Nogueira, Nelson Dinamarco Members: Dilma do Socorro Moraes de Souza, Lilian
Load more

Recommended publications
  • Guidelines on Paediatric Urology S
    Guidelines on Paediatric Urology S. Tekgül (Chair), H.S. Dogan, E. Erdem (Guidelines Associate), P. Hoebeke, R. Ko˘cvara, J.M. Nijman (Vice-chair), C. Radmayr, M.S. Silay (Guidelines Associate), R. Stein, S. Undre (Guidelines Associate) European Society for Paediatric Urology © European Association of Urology 2015 TABLE OF CONTENTS PAGE 1. INTRODUCTION 7 1.1 Aim 7 1.2 Publication history 7 2. METHODS 8 3. THE GUIDELINE 8 3A PHIMOSIS 8 3A.1 Epidemiology, aetiology and pathophysiology 8 3A.2 Classification systems 8 3A.3 Diagnostic evaluation 8 3A.4 Disease management 8 3A.5 Follow-up 9 3A.6 Conclusions and recommendations on phimosis 9 3B CRYPTORCHIDISM 9 3B.1 Epidemiology, aetiology and pathophysiology 9 3B.2 Classification systems 9 3B.3 Diagnostic evaluation 10 3B.4 Disease management 10 3B.4.1 Medical therapy 10 3B.4.2 Surgery 10 3B.5 Follow-up 11 3B.6 Recommendations for cryptorchidism 11 3C HYDROCELE 12 3C.1 Epidemiology, aetiology and pathophysiology 12 3C.2 Diagnostic evaluation 12 3C.3 Disease management 12 3C.4 Recommendations for the management of hydrocele 12 3D ACUTE SCROTUM IN CHILDREN 13 3D.1 Epidemiology, aetiology and pathophysiology 13 3D.2 Diagnostic evaluation 13 3D.3 Disease management 14 3D.3.1 Epididymitis 14 3D.3.2 Testicular torsion 14 3D.3.3 Surgical treatment 14 3D.4 Follow-up 14 3D.4.1 Fertility 14 3D.4.2 Subfertility 14 3D.4.3 Androgen levels 15 3D.4.4 Testicular cancer 15 3D.5 Recommendations for the treatment of acute scrotum in children 15 3E HYPOSPADIAS 15 3E.1 Epidemiology, aetiology and pathophysiology
    [Show full text]
  • Summary of Product Characteristics
    SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT *IPERTEN/ARTEDIL/MANYPER 10mg tablets IPERTEN/ARTEDIL/MANYPER 20mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION IPERTEN/ARTEDIL/MANYPER 10 mg tablets Each tablet contains: Manidipine hydrochloride 10mg Excipient with known effect: 119,61 mg lactose monohydrate/tablet IPERTEN/ARTEDIL/MANYPER 20 mg tablets Each tablet contains: Manidipine hydrochloride 20mg Excipient with known effect: 131,80 mg lactose monohydrate/tablet For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet IPERTEN/ARTEDIL/MANYPER 10mg: pale yellow, round, scored tablet; IPERTEN/ARTEDIL/MANYPER 20mg: yellow-orange, oblong, scored tablet. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Mild to moderate essential hypertension 4.2 Posology and method of administration The recommended starting dose is 10 mg once a day. Should the antihypertensive effect be still insufficient after 2-4 weeks of treatment, it is advisable to increase the dosage to the usual maintenance dose of 20 mg once a day. Elderly In view of the slowing down of metabolism in the elderly, the recommended dose is 10mg once daily. This dosage is sufficient in most elderly patients; the risk/benefit of any dose increase should be considered with caution on an individual basis. Renal impairment In patients with mild to moderate renal dysfunction care should be taken when increasing the dosage from 10 to 20mg once a day. Hepatic impairment Due to the extensive hepatic metabolisation of manidipine, patients with mild hepatic dysfunction should not exceed 10mg once a day (see also Section 4.3 Contraindications). Tablet must be swallowed in the morning after breakfast, without chewing it, with a few liquid.
    [Show full text]
  • The Repurposing Drugs in Oncology Database
    ReDO_DB: the repurposing drugs in oncology database Pan Pantziarka1,2, Ciska Verbaanderd1,3, Vidula Sukhatme4, Rica Capistrano I1, Sergio Crispino1, Bishal Gyawali1,5, Ilse Rooman1,6, An MT Van Nuffel1, Lydie Meheus1, Vikas P Sukhatme4,7 and Gauthier Bouche1 1The Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium 2The George Pantziarka TP53 Trust, London, UK 3Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium 4GlobalCures Inc., Newton, MA 02459 USA 5Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115 USA 6Oncology Research Centre, Vrije Universiteit Brussel, Brussels, Belgium 7Emory University School of Medicine, Atlanta, GA 30322 USA Correspondence to: Pan Pantziarka. Email: [email protected] Abstract Repurposing is a drug development strategy that seeks to use existing medications for new indications. In oncology, there is an increased level of activity looking at the use of non-cancer drugs as possible cancer treatments. The Repurposing Drugs in Oncology (ReDO) project has used a literature-based approach to identify licensed non-cancer drugs with published evidence of anticancer activity. Data from 268 drugs have been included in a database (ReDO_DB) developed by the ReDO project. Summary results are outlined and an assessment Research of clinical trial activity also described. The database has been made available as an online open-access resource (http://www.redo-project. org/db/). Keywords: drug repurposing, repositioning, ReDO project, cancer drugs, online database Published: 06/12/2018 Received: 27/09/2018 ecancer 2018, 12:886 https://doi.org/10.3332/ecancer.2018.886 Copyright: © the authors; licensee ecancermedicalscience.
    [Show full text]
  • IPEG's 25Th Annual Congress Forendosurgery in Children
    IPEG’s 25th Annual Congress for Endosurgery in Children Held in conjunction with JSPS, AAPS, and WOFAPS May 24-28, 2016 Fukuoka, Japan HELD AT THE HILTON FUKUOKA SEA HAWK FINAL PROGRAM 2016 LY 3m ON m s ® s e d’ a rl le o r W YOU ASKED… JustRight Surgical delivered W r o e r l ld p ’s ta O s NL mm Y classic 5 IPEG…. Now it’s your turn RIGHT Come try these instruments in the Hands-On Lab: SIZE. High Fidelity Neonatal Course RIGHT for the Advanced Learner Tuesday May 24, 2016 FIT. 2:00pm - 6:00pm RIGHT 357 S. McCaslin, #120 | Louisville, CO 80027 CHOICE. 720-287-7130 | 866-683-1743 | www.justrightsurgical.com th IPEG’s 25 Annual Congress Welcome Message for Endosurgery in Children Dear Colleagues, May 24-28, 2016 Fukuoka, Japan On behalf of our IPEG family, I have the privilege to welcome you all to the 25th Congress of the THE HILTON FUKUOKA SEA HAWK International Pediatric Endosurgery Group (IPEG) in 810-8650, Fukuoka-shi, 2-2-3 Jigyohama, Fukuoka, Japan in May of 2016. Chuo-ku, Japan T: +81-92-844 8111 F: +81-92-844 7887 This will be a special Congress for IPEG. We have paired up with the Pacific Association of Pediatric Surgeons International Pediatric Endosurgery Group (IPEG) and the Japanese Society of Pediatric Surgeons to hold 11300 W. Olympic Blvd, Suite 600 a combined meeting that will add to our always-exciting Los Angeles, CA 90064 IPEG sessions a fantastic opportunity to interact and T: +1 310.437.0553 F: +1 310.437.0585 learn from the members of those two surgical societies.
    [Show full text]
  • Ovid MEDLINE(R)
    Supplementary material BMJ Open Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 16, 2019> # Searches Results 1 exp Hypertension/ 247434 2 hypertens*.tw,kf. 420857 3 ((high* or elevat* or greater* or control*) adj4 (blood or systolic or diastolic) adj4 68657 pressure*).tw,kf. 4 1 or 2 or 3 501365 5 Sex Characteristics/ 52287 6 Sex/ 7632 7 Sex ratio/ 9049 8 Sex Factors/ 254781 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 336361 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 52111 (therap* or treat* or effective*))).tw,kf. 14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or 20534 antagonist*)).tw,kf. 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or 86627 azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil
    [Show full text]
  • 174-Atypical Antipsychotics and Sleepwalkingsleep-Related Eating
    Atypical antipsychotics and sleepwalking/sleep-related eating disorder CONFIDENTIAL Medicines Adverse Reactions Committee Meeting date 3 July 2018 Agenda item 3.2.2 Title Atypical antipsychotics and sleepwalking/sleep-related eating disorder Medsafe For advice Submitted by Paper type Pharmacovigilance Team Active constituent Medicine Sponsors Amisulpride Solian Sanofi-Aventis Sulprix Mylan Aripiprazole Abilify Pharmacy Retailing Aripiprazole Sandoz Novartis Clozapine Clopine Douglas Pharmaceuticals Clozaril Mylan Olanzapine Olanzapine DRLA Dr Reddy’s Zypine Mylan Zyprexa Eli Lilly Paliperidone Invega Janssen-Cilag Quetiapine Auro-Quetiapine Aurobindo Pharma DP-Quetiapine Douglas Pharmaceuticals Quetapel Mylan Quetiapine DRLA Dr Reddy’s Seroquel AstraZeneca Risperidone Ridal Douglas Pharmaceuticals Risperdal Janssen-Cilag Risperidone DRLA Dr Reddy’s Risperidone (Teva) Teva Pharma Risperon Mylan Ziprasidone Zeldox Pfizer Zusdone Douglas Pharmaceuticals Funding All of the above active constituents have a funded brand with the exception of paliperidone. The special authority criteria for aripiprazole was removed on 1 June 2018. Previous MARC Atypical antipsychotics and sleepwalking/sleep-related eating disorder has meetings not been discussed previously. International action Health Canada − In September 2017, Health Canada issued a safety review on the potential risk of sleepwalking and sleep-related eating disorder associated with atypical antipsychotics. Based on this review, Health Canada has recommended updating the product safety information
    [Show full text]
  • Ultrasonographic and Radiographic Diagnosis of Ectopic Ureter in a Dog
    Acta Scientiae Veterinariae, 2021. 49(Suppl 1): 613. CASE REPORT ISSN 1679-9216 Pub. 613 Ultrasonographic and Radiographic Diagnosis of Ectopic Ureter in a Dog Carmen Vládia Soares de Sousa, Caroline Coelho Rocha, Roberto Sávio Bessa da Silva, Araceli Alves Dutra, Brizza Zorayd Luz Lopes Rocha, Thays Ribeiro Pacó & João Marcelo Azevedo de Paula Antunes ABSTRACT Background: Ureteral ectopia (or ectopic ureter) is a congenital anomaly of the urinary system in which the ureter inserts anywhere other than the vesical trigone. This anatomical change may have unilateral or bilateral involvement. The most evident clinical sign, occurring mostly in females, is urinary incontinence, however in some cases the condition may progress to nephritis and dilation of the renal pelvis. The diagnosis is established through imaging, and definitive treatment requires surgical approach. The present study reports a case of ureteral ectopia in a dog which was diagnosed by ultrasound and contrast radiography (excretory urography) and successfully treated by neoureterostomy. Case: A 10-month-old female American Pit Bull Terrier was attended at the Veterinary Hospital of the Federal Rural Uni- versity of the Semi-Arid (UFERSA), in Mossoró, RN. Her owner reported incontinence of dark, malodorous urine since birth as the chief complaint. After clinical examination, cystitis was suspected, and a complete blood count, urinalysis, and abdominal ultrasound was requested. The blood count and creatinine were within the reference values. The presence of struvite crystals were found on urinalysis. Ultrasound examination revealed a tortuous, dilated right ureter from the renal pelvis to the urinary bladder; no uroliths were identified as a cause of potential obstruction, but the ipsilateral kidney showed increased cortical echogenicity, loss of corticomedullary definition, and moderate pelvic dilation.
    [Show full text]
  • Specialist Clinic Referral Guidelines UROLOGY
    Specialist Clinic Referral Guidelines UROLOGY Please fax referrals to The Alfred Specialist Clinics on 9076 6938. The Alfred Specialist Clinics Referral Form is available to print and fax. Where appropriate and available, the referral may be directed to an alternative specialist clinic or service. Advice regarding referral for specific conditions to the Alfred Urology Service can be found here. The clinical information provided in the referral will determine the triage category. The triage category will affect the timeframe in which the patient is offered an appointment. Notification will be sent when the referral is received. The referral may be declined if it does not contain essential information required for triage, if the condition is not appropriate for referral to a public hospital, or is a condition not routinely seen at Alfred Health. Referral to Victorian public hospitals is not appropriate for: Mild to moderate lower urinary tract symptoms that have not been treated Lower urinary tract symptoms that have responded to medical management Simple renal cysts Asymptomatic epididymal cyst not identified through ultrasound Patients who have not yet tried, or failed, conservative treatment for urinary incontinence Cosmetic surgery including circumcision, penile enhancements & penile implants (see Victorian DHHS Aesthetic procedures and indications for surgery in Victorian public health services.) The following conditions are not routinely seen at Alfred Health: Patients who are being treated for the same condition at another Victorian public hospital Children under 18 years of age Vasectomy reversal Erectile dysfunction unrelated to previous surgery, trauma or radiation therapy Infertility Surgery Please refer to the Department of Health and Human Services (DHHS) Statewide Referral Criteria for Specialist Clinics for further information when referring to Urology specialist clinics in public hospitals.
    [Show full text]
  • Exploring Inflammatory Status in Febrile Seizures Associated With
    brain sciences Article Exploring Inflammatory Status in Febrile Seizures Associated with Urinary Tract Infections: A Two-Step Cluster Approach Raluca Maria Costea 1,2,3,* , Ionela Maniu 1,4 , Luminita Dobrota 3, Rubén Pérez-Elvira 5 , Maria Agudo 5, Javier Oltra-Cucarella 6 , Andrei Dragomir 7 , Ciprian Bacilă 3, Adela Banciu 8, Daniel Dumitru Banciu 8, 3 3 1,3,9, Călin Remus Cipăian , Roxana Cris, an and Bogdan Neamtu * 1 Pediatric Research Department, Pediatric Clinical Hospital Sibiu, 550166 Sibiu, Romania; [email protected] 2 Pediatric Neurology Department, Pediatric Clinical Hospital Sibiu, 550166 Sibiu, Romania 3 Faculty of Medicine, Lucian Blaga University of Sibiu, 550024 Sibiu, Romania; [email protected] (L.D.); [email protected] (C.B.); [email protected] (C.R.C.); [email protected] (R.C.) 4 Research Center in Informatics and Information Technology, Mathematics and Informatics Department, Faculty of Sciences, Lucian Blaga University of Sibiu, 550024 Sibiu, Romania 5 Neuropsychophysiology Laboratory, NEPSA Rehabilitación Neurológica, 37003 Salamanca, Spain; [email protected] (R.P.-E.); [email protected] (M.A.) 6 Department of Health Psychology, Universidad Miguel Hernández de Elche, 03202 Elche, Spain; [email protected] 7 N.1 Institute for Health, National University of Singapore, Singapore 117575, Singapore; [email protected] 8 Department of Bioengineering and Biotechnology, Faculty of Medical Engineering, Citation: Costea, R.M.; Maniu, I.; Politechnic University of Bucharest, 011061 Bucharest, Romania; [email protected] (A.B.); Dobrota, L.; Pérez-Elvira, R.; Agudo, [email protected] (D.D.B.) 9 Computer and Electrical Engineering Department, Faculty of Engineering, Lucian Blaga University of Sibiu, M.; Oltra-Cucarella, J.; Dragomir, A.; 550024 Sibiu, Romania Bacil˘a,C.; Banciu, A.; Banciu, D.D.; * Correspondence: [email protected] (R.M.C.); [email protected] (B.N.); et al.
    [Show full text]
  • Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: an Overview of Systematic Reviews
    Supplementary Online Content Karmali KN, Lloyd-Jones DM, Berendsen MA, et al. Drugs for primary prevention of atherosclerotic cardiovascular disease: an overview of systematic reviews. JAMA Cardiol. Published online April 27, 2016. doi:10.1001/jamacardio.2016.0218. eAppendix 1. Search Documentation Details eAppendix 2. Background, Methods, and Results of Systematic Review of Combination Drug Therapy to Evaluate for Potential Interaction of Effects eAppendix 3. PRISMA Flow Charts for Each Drug Class and Detailed Systematic Review Characteristics and Summary of Included Systematic Reviews and Meta-analyses eAppendix 4. List of Excluded Studies and Reasons for Exclusion This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. 1 Downloaded From: https://jamanetwork.com/ on 09/28/2021 eAppendix 1. Search Documentation Details. Database Organizing body Purpose Pros Cons Cochrane Cochrane Library in Database of all available -Curated by the Cochrane -Content is limited to Database of the United Kingdom systematic reviews and Collaboration reviews completed Systematic (UK) protocols published by by the Cochrane Reviews the Cochrane -Only systematic reviews Collaboration Collaboration and systematic review protocols Database of National Health Collection of structured -Curated by Centre for -Only provides Abstracts of Services (NHS) abstracts and Reviews and Dissemination structured abstracts Reviews of Centre for Reviews bibliographic
    [Show full text]
  • Urology Referral Guidelines
    Urology Referral Guidelines Department of Health clinical urgency categories for specialist clinics Urgent: A referral is urgent if the patient has a condition that has major functional impairment and/or moderate risk of permanent damage to an organ/bone/tissue/system if not seen within 30 days. Semi Urgent: Referrals should be categorised as Semi Urgent where the patient has a condition that has the potential to deteriorate within 30-90 days. Routine: Referrals should be categorised as routine if the patient’s condition is unlikely to deteriorate quickly or have significant consequences for the person’s health and quality of life if specialist assessment is delayed beyond one month. Exclusions: Austin Health do not perform the following procedures commonly conducted by Urology Units: Refer all erectile dysfunction to Austin’s Men’s Health Clinic Refer all female Bladder Prolapse, Pelvic Prolapse, Cystocele to Mercy or Women’s Hospital Condition / Symptom Criteria for Referral Information to be Expected Triage Austin Specific included Outcome Guidance Notes These guidelines have been set by DHHS: src.health.vic.gov.au Haematuria 1. Any visible haematuria Must be provided: Urgent Instruct patient to bring 2. Persistent microscopic 1. Midstream urine microscopy - Macroscopic films to the Specialist Direct to Emergency Department haematuria: at least 2 episodes culture sensitivities Clinic appointment for: confirmed through midstream 2. Creatinine & Electrolytes (U&E) Semi-urgent specimen of urine collected at 3. Urinary Tract Ultrasound or CT - Microscopic Severe urinary tract least a week apart. Intravenous Pyelogram results bleeding 3. Macroscopic haematuria in the (IVP) absence of a urinary tract infection.
    [Show full text]
  • Interactions Between Antihypertensive Drugs and Food B
    11. INTERACTIONS:01. Interacción 29/11/12 14:38 Página 1866 Nutr Hosp. 2012;27(5):1866-1875 ISSN 0212-1611 • CODEN NUHOEQ S.V.R. 318 Revisión Interactions between antihypertensive drugs and food B. Jáuregui-Garrido1 and I. Jáuregui-Lobera2 1Department of Cardiology. University Hospital Virgen del Rocío. Seville. Spain. 2Bromatology and Nutrition. Pablo de Olavide University. Seville. Spain. Abstract INTERACCIONES ENTRE FÁRMACOS ANTIHIPERTENSIVOS Y ALIMENTOS Objective: A drug interaction is defined as any alter- ation, pharmacokinetics and/or pharmacodynamics, Resumen produced by different substances, other drug treatments, dietary factors and habits such as drinking and smoking. Objetivo: la interacción de medicamentos se define como These interactions can affect the antihypertensive drugs, cualquier alteración, farmacocinética y/o farmacodiná- altering their therapeutic efficacy and causing toxic mica, producida por diferentes sustancias, otros tratamien- effects. The aim of this study was to conduct a review of tos, factores dietéticos y hábitos como beber y fumar. Estas available data about interactions between antihyperten- interacciones pueden afectar a los fármacos antihipertensi- sive agents and food. vos, alterando su eficacia terapéutica y causando efectos Methods: The purpose of this review was to report an tóxicos. El objetivo de este estudio fue realizar una revisión update of main findings with respect to the interactions de los datos disponibles acerca de las interacciones entre los between food and antihypertensive drugs
    [Show full text]